"Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight," John Sharretts, the FDA's diabetes and obesity czar, said in the press release.
Last August, Novo announced that semaglutide had showed significant heart health benefits in a large-scale human trial.
[
add
]
[
|
|
...
]